Table 3.
Upregulated and Downregulated Pathways of Differentially Expressed Genes
| Upregulated IPA Pathways: PH(90%) Versus All Other Groups (n = 20) |
| 1. EIF2 signaling |
| 2. Cell cycle: G2/M DNA damage checkpoint regulation |
| 3. GADD45 signaling |
| 4. Mitotic roles of Polo-like kinase |
| 5. Regulation of eIF4 and p70S6K |
| 6. Cell cycle control of chromosomal replication |
| 7. mTOR signaling |
| 8. Estrogen-mediated S-phase entry |
| 9. Cyclins and cell cycle regulation |
| 10. Role of CHK proteins in cell cycle checkpoint control |
| 11. Hereditary breast cancer signaling |
| 12. RAN signaling |
| 13. ILK signaling |
| 14. ATM signaling |
| 15. DNA damage-induced 14-3-3o signaling |
| 16. Cell cycle: G1/S checkpoint regulation |
| 17. Stearate biosynthesis I |
| 18. Acyl-CoA hydrolysis |
| 19. Cell cycle regulation by BTG family proteins |
| 20. Breast cancer regulation by stathmin 1 |
| Downregulated IPA Pathways: PH(90%) Versus All Other Groups (n = 72) |
| 1. Acetone degradation I (to methylglyoxal) |
| 2. Adenosine nucleotide degradation II |
| 3. Androgen biosynthesis |
| 4. Aryl hydrocarbon signaling |
| 5. Bile acid biosynthesis, neutral pathway |
| 6. Bupropion degradation |
| 7. Cell cycle control of chromosomal replication |
| 8. Cell cycle: G2/M DNA damage checkpoint regulation |
| 9. Cholesterol biosynthesis I |
| 10. Cholesterol biosynthesis II (via 24,25-dihydrolanosterol) |
| 11. Cholesterol biosynthesis III (via desmosterol) |
| 12. Citrulline biosynthesis |
| 13. Complement system |
| 14. DNA damage-induced 14-3-3o signaling |
| 15. Dopamine degradation |
| 16. Estrogen biosynthesis |
| 17. Estrogen-mediated S-phase entry |
| 18. Ethanol degradation II |
| 19. Ethanol degradation IV |
| 20. Fatty acid activation |
| 21. Fatty acid α-oxidation |
| 22. Fatty acid β-oxidation I |
| 23. FXR/RXR activation |
| 24. γ-Glutamyl cycle |
| 25. γ-Linolenate biosynthesis II |
| 26. Glucocorticoid biosynthesis |
| 27. Glutaryl-CoA degradation |
| 28. Glutathione-mediated detoxification |
| 29. Glycine betaine degradation |
| 30. Guanosine nucleotides degradation III |
| 31. Histamine degradation |
| 32. Leucine degradation |
| 33. LPS/IL-1-mediated inhibition of RXR function |
| 34. LXR/RXR activation |
| 35. Melatonin degradation I |
| 36. Methylglyoxal degradation III |
| 37. Mineralocorticoid biosynthesis |
| 38. Mitochondrial l-carnitine shuttle pathway |
| 39. Mitotic roles of Polo-like kinase |
| 40. Molybdenum cofactor biosynthesis |
| 41. NAD biosynthesis II (from tryptophan) |
| 42. Nicotine degradation II |
| 43. Nicotine degradation III |
| 44. Noradrenaline and adrenaline degradation |
| 45. NRF2-mediated oxidative stress response |
| 46. Oleate biosynthesis II |
| 47. Oxidative ethanol degradation III |
| 48. Proline degradation |
| 49. Putrescine degradation III |
| 50. PXR/RXR activation |
| 51. Retinol biosynthesis |
| 52. Role of BRCA1 in DNA damage response |
| 53. Serotonin degradation |
| 54. Stearate biosynthesis I |
| 55. Sucrose degradation |
| 56. Superoxide radicals degradation |
| 57. Superpathway of cholesterol biosynthesis |
| 58. Superpathway of melatonin degradation |
| 59. Superpathway of methionine degradation |
| 60. Taurine biosynthesis |
| 61. The visual cycle |
| 62. Thymine degradation |
| 63. Thyroid hormone metabolism II (via conjugation and/or degradation) |
| 64. TR/RXR activation |
| 65. Triacylglycerol degradation |
| 66. Tryptophan degradation III |
| 67. Tryptophan degradation to 2-amino-3-carboxymuconate semialdehyde |
| 68. Tryptophan degradation X (mammalian, via tryptamine) |
| 69. Uracil degradation II (reductive) |
| 70. Urate biosynthesis/inosine 5*-phosphate degradation |
| 71. Xenobiotic metabolism signaling |
| 72. Zymosterol biosynthesis |